Beyond The Graft: Synthetic Scaffolds For Soft-Tissue Reconstruction

A field littered with failures sees few companies brave enough to try again. A big market awaits medtech start-ups that find a successful way to end the need for autografts and allografts for soft-tissue repair.

Silver wire and carbon fiber; polyethylene, Dacron, and Gor-Tex: these are just some among the synthetic materials device makers have fashioned into ropes, cuffs, and straps to replace torn and ruptured ligaments and tendons. These prosthetic anterior cruciate ligaments, Achilles and elbow tendons, rotator cuffs, and more have often failed or sometimes set off such serious biomechanical, health, or immunogenic complications that surgeons needed to remove them. After a century of efforts to fashion synthetic implants, every attempt so far has fallen short of human tissue’s particular combination of biology, strength, flexibility, stability, and endurance. Surgeons must still rely either on transplanting human tissue harvested from a patient’s own body – autografts – or a cadaver – allografts – to rebuild seriously damaged soft connective tissue.

Surgeons fix ankle, knee, shoulder, and other soft-tissue tears and ruptures more than a million times a year, yet autografts and allografts, too, have important drawbacks. Autografts require cutting as much as a third of a patient’s tendon, weakening it, causing site pain and potential morbidity, biomechnical insufficiency, extended surgery time, and long recovery; allografts obviate the need to cut and damage the patient’s own tissue, but raise red flags from concerns about possible disease transmission – along with the potential for failure due to structural weakness in the allograft caused by sterilization processes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Dexcom Puts Stelo On Amazon, Setting Up Consumer Showdown With Abbott

 
• By 

In addition to broader distribution, Dexcom is investing heavily in software enhancements for Stelo. The 180-day data lookback feature is just one of several planned upgrades intended to improve personalization and user engagement.

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By 

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.

Does Makary’s Reorg Choice Mark FDA Turning Point?

 

US FDA Commissioner Martin Makary’s disavowal of a proposed reorganization plan may be an important turning point in the Trump Administration. The move does not improve the situation, but may mean the administration stops actively making things worse.